Sanofi gets expanded meningitis vaccine approval

Apr 25, 2011

(AP) -- Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said Monday the Food and Drug Administration approved the company's bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months.

The disease is fairly rare in the United States, but those who get it develop symptoms quickly and can die in only a few days. Survivors can suffer mental disabilities, hearing loss and paralysis. The is spread by coughing, sneezing and kissing, and most cases occur in previously healthy children and young adults.

The company said this is the first U.S. approval for a bacterial for the age group between 9 months and 23 months.

Menactra was already approved for people ages 11 through 55 and children between 2 and 10 years old.

Explore further: US appeals court upholds delay in Alzheimer's drug swap

0 shares

Related Stories

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

CDC panel: Teens need another meningitis shot

Oct 27, 2010

(AP) -- Teens should get a booster dose of the vaccine for bacterial meningitis because a single shot doesn't work as long as expected, a federal advisory panel said Wednesday.

ActHIB vaccine recalled in Japan

Mar 11, 2011

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.